Analyst Research

Report Title Price
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

NxStage Medical Inc Issues Q4 Guidance Below Analysts' Estimates; Lowers FY 2013 Guidance


Thursday, 7 Nov 2013 07:32am EST 

NxStage Medical Inc announced that for the fourth quarter of 2013, it expects revenues to be between $67.0-$68.5 million, and a net loss in the range of $6.0-$5.0 million, or ($0.10) to ($0.08) per share. For fiscal 2013, it expects revenue to be within a range of $261.0-$262.5 million and a net loss in the range of $19.5-$18.5 million, or ($0.32) to ($0.31) per share, compared with the Company's fiscal 2013 revenue to be a range of $265-$270 million and a net loss in the range of $17-$13 million, or ($0.28) to ($0.22) per share. The components of the Company's revised fiscal 2013 revenue guidance include Home at 6.5% to 7.5%, Critical Care at approximately 10%, and In-Center at 6% to 7% annual growth. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $71 million, net income of $(3) million, EPS of $(0.05) for the fourth quarter of 2013 and revenue of $265 million, net income of $(16) million and EPS of $(0.26) for fiscal 2013. 

Company Quote

13.5
0.1 +0.75%
29 Jul 2014